Abivax (AAVXF) Total Non-Current Liabilities (2021 - 2026)

Abivax has reported Total Non-Current Liabilities for 6 years, with the latest figure at $64.8 million in Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities fell 9.18% year-over-year to $64.8 million in Q1 2026; TTM through Mar 2026 was $64.8 million, a 9.18% decrease from a year earlier, with the FY2025 full-year figure at $77.0 million, up 1.95% from the prior year.
• Total Non-Current Liabilities was $64.8 million for Q1 2026 at Abivax, down from $77.0 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $84.1 million in Q2 2024, with the low at $17.2 million in Q4 2022.
• Average Total Non-Current Liabilities over 5 years is $63.2 million, with a median of $71.3 million recorded in 2025.
• The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities tumbled 70.48% in 2022, then soared 151.96% in 2023.
• Over 5 years, Total Non-Current Liabilities stood at $17.2 million in 2022, then jumped by 151.96% to $43.4 million in 2023, then jumped by 73.86% to $75.5 million in 2024, then rose by 1.95% to $77.0 million in 2025, then dropped by 15.85% to $64.8 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $64.8 million (Q1 2026), $77.0 million (Q4 2025), and $72.5 million (Q3 2025), per Business Quant data.